Ghassan K. Abou-Alfa, MD, on HCC: Results From the CELESTIAL Trial

2018 Gastrointestinal Cancers Symposium
Tweet this page

Ghassan K. Abou-Alfa, MD, of Memorial Sloan Kettering Cancer Center, discusses phase III study findings on cabozantinib vs placebo in patients with advanced hepatocellular carcinoma who have received prior treatment with sorafenib (Abstract 207).